Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria

4 May 2019

Abstract excerpt

Hydroxyurea (HU) is a well-known Hb F-inducing agent with proven clinical and laboratory efficacy for patients with sickle cell disease. However, concerns about its long-term safety and toxicity have limited its prescription by physicians and acceptability by patients. Thus, this study aims to evaluate clinician's barriers to the use of HU in the management of patients with sickle cell disease in Nigeria. An...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31462098
DOI: 10.1080/03630269.2019.1649278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Barriers to the use of hydroxyurea in the management of sickle cell disease in NigeriaPMID 31462098Read ↗

Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider NetworkSemantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaSemantic proximity Read ↗

Economic Burden and Clinical Effectiveness of Different Hydroxyurea Dosing Regimens in Sickle Cell Disease: Evidence from NepalSemantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Gene polymorphisms predicting response to hydroxyurea treatment in Bahraini patients with sickle cell disease.Semantic proximity Read ↗

Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.Semantic proximity Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

Fixed Low-Dose Hydroxyurea Therapy: A Strategy for Reducing Emergency Room Visits and Improving Treatment Adherence in Paediatric Sickle Cell Anaemia in Resource-Limited SettingsSemantic proximity Read ↗

Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-ThalassemiaSemantic proximity Read ↗

Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.Semantic proximity Read ↗

Pregnancy outcomes with hydroxyurea use in women with sickle cell diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.